Novartis Drug for Smoker’s Cough Boosts Lung Function in Study

Novartis AG’s experimental drug for smoker’s cough helped patients in a late-stage trial, and was at least as good as a treatment sold by Boehringer Ingelheim GmbH and Pfizer Inc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.